On January 17, 2014, the President signed the Consolidated Appropriations Act, 2014 , into law. NIH fiscal policies implementing the Act are described in NIH Fiscal Policy for Grant Awards – FY 2014. NIGMS fiscal policies for FY 2014 are described below.
Research Project Grants (RPGs)
- Noncompeting RPGs: All noncompeting grants will be funded at the committed levels. Those already funded at 90 percent will be restored to the committed levels.
- Competing RPGs: The overall average cost will be at approximately 2 percent above the FY 2013 level.
The SBIR/STTR Reauthorization Act of 2011 mandates an increase in the set-aside for the combined SBIR/STTR programs to 3.2 percent in FY 2014. Noncompeting SBIR/STTR awards will be funded at the committed levels.
- Noncompeting IDeA and AIDS centers will be funded at the committed levels. Other P41, P50 and U54 noncompeting awards will be reduced by 10 percent from the committed levels. Those already funded at levels below 90 percent will be revised accordingly. Out-year commitments for FY 2015 and beyond will remain unchanged.
- The funds available for new and competing awards in response to funding opportunity announcements will be reduced by approximately 50 percent of the amounts listed in the announcements.
Noncompeting conference (R13/U13), career (K), IMSD, RISE, SCORE, Bridges and PREP awards will be funded at the committed levels.
Ruth L. Kirschstein National Research Service Awards (NRSA)
Consistent with the Consolidated Appropriations Act, 2014 , and with the recommendations of the Advisory Committee to the Director regarding the Biomedical Research Workforce, NIH, including NIGMS, will increase undergraduate and graduate student stipends by 2 percent. Entry-level postdoctoral stipends will be increased to $42,000, with 4 percent increases between the individual levels of experience. The full range of stipend adjustments for FY 2014 is described at NOT-OD-14-046.
NIH, including NIGMS, will continue to support new investigators on R01-equivalent awards at success rates comparable to those of established investigators submitting new (Type 1) R01-equivalent applications.